KARACHI: When Pakistan's hepatitis C epidemic finally met a cure, the name attached to the breakthrough treatment was not one of the multinational giants. It was Ferozsons Laboratories — FEROZ on the Pakistan Stock Exchange — the company chosen by America's Gilead Sciences as its Pakistan partner for Sovaldi, the sofosbuvir tablet that transformed hepatitis C from a slow, feared disease into a curable one. That partnership, and a string of similar ones covering hepatitis B and HIV, explains why a mid-sized Pakistani drugmaker punches so far above its weight in public-health history. For a beginner browsing the PSX pharmaceutical stocks, Ferozsons is the specialist: a company built less on a giant catalogue than on being the local partner global medicine trusts with its hardest products.
Why a mid-sized drugmaker became a national name
Pakistan carries one of the world's heaviest burdens of viral hepatitis, and Ferozsons organised much of its modern identity around that fact. Its hepatology franchise — medicines for hepatitis B and C — sits inside a broader portfolio spanning gastroenterology, cardiology and oncology, with growing lines in diabetes and endocrinology and in mother-and-child health. Alongside its own manufactured brands, the company distributes and co-manufactures products for international partners, and it owns the controlling story of BF Biosciences, the joint venture that built Pakistan's first biotech medicines plant.
The result is a company whose reputation in doctors' surgeries and health ministries is larger than its sales rank among Pakistan's drugmakers. Ferozsons repeatedly appears at the moments when a new, expensive global therapy needs a credible local route to Pakistani patients at a price patients can reach — hepatitis C in the last decade, a Covid-19 antiviral during the pandemic, and a long-acting HIV medicine in the current one.
Origins: incorporated in 1954, listed in 1960
Ferozsons was incorporated as a private limited company on 28 January 1954 and converted into a public limited company on 8 September 1960. Company leadership takes pride in a specific distinction: Ferozsons describes itself as the first Pakistani pharmaceutical company to list on the Karachi Stock Exchange, in 1960 — a strikingly early embrace of public ownership for a family-founded enterprise of that era, and, in the words of its chief executive at a later listing ceremony, part of the founder's vision of shared national ownership in the business.
The company's registered roots are in Rawalpindi, where its historic head office stood on The Mall, and its long-standing factory at Amangarh, near Nowshera in Khyber Pakhtunkhwa, anchored its manufacturing for decades. Over time a major Lahore presence grew — the operations along the Sundar Raiwind Road south of Lahore are the address most partners and suppliers now associate with the group — which is why Ferozsons is so often described, including in its own hook on this site, as a Lahore pharma. The honest geography is both: a Rawalpindi-born company whose centre of gravity shifted towards Lahore as it grew.
Partnerships as a business strategy
What sets Ferozsons apart is that partnerships are not a sideline; they are the strategy. In 2002 it entered a commercial partnership with Argentina's Bagó Group to launch Bagó's branded generics in oncology and hepatology in Pakistan. In December 2004 the two agreed in principle to go further, and in 2006 they formed BF Biosciences Limited — described at its birth as Pakistan's first biotech formulation company. BF's plant took on the biologics Pakistan had been importing at punishing prices: interferons for hepatitis B and C and erythropoietin for chronic kidney disease, with company leadership later crediting local production with cutting treatment costs by more than sixty per cent. BF Biosciences has since expanded into human insulin, heparins and modern diabetes medicines, and it listed on the PSX in its own right in 2024 — six decades after its parent's own listing.
The defining partnership, though, is with Gilead Sciences. Ferozsons partnered with Gilead in 2014 around the launch of its breakthrough hepatitis C treatment, becoming Gilead's authorised partner for its hepatitis B, hepatitis C and HIV portfolio in Pakistan, with an in-country licence to manufacture authorised generics of Gilead's hepatitis C products. When Covid-19 arrived, Gilead selected Ferozsons as one of its international voluntary licensees to produce remdesivir for patients in low- and lower-middle-income countries. More recently Ferozsons was named among six global generic partners licensed to produce lenacapavir, Gilead's long-acting HIV medicine, for supply across the countries covered by the licence — with the injectable version to be made through BF Biosciences and the oral version by Ferozsons itself. Around these sit smaller exclusive arrangements, from Biofreeze pain-relief products to Boston Scientific's interventional medical devices, which Ferozsons distributes in Pakistan.
What Ferozsons actually makes and sells
Strip away the partnerships and a substantial conventional drugmaker remains. Ferozsons manufactures and sells pharmaceutical products across the classic therapeutic map: antibacterials and antivirals, anti-ulcer and other gastroenterology medicines, antihypertensives and cardiology lines, analgesics and anti-inflammatory products, cough preparations, multivitamins, anti-diabetic medicines and an oncology range. Its own disclosures emphasise leadership brands in gastroenterology, hepatology, cardiology and oncology, with an emerging presence in endocrinology, diabetes and mother-and-child health. Alongside manufacturing, the company is engaged in importing and in the retail trading and distribution of pharmaceutical products and medical devices, and it exports to markets in Africa, Central Asia and the Middle East.
That mixture — own brands, licensed originator products, authorised generics, distributed devices and a listed biotech subsidiary — makes Ferozsons harder to summarise than a peer such as GlaxoSmithKline Pakistan, whose catalogue descends from one global parent. Ferozsons is better pictured as a platform: manufacturing credibility and regulatory relationships in Pakistan, onto which global partners plug products that need exactly that credibility.
How Ferozsons makes money
The revenue engine has three cylinders. The first is the sale of its own manufactured brands to pharmacies, hospitals and doctors, at prices shaped — as for every Pakistani drugmaker — by the national regulator's pricing framework; volumes depend on prescription habits built over years by its medical sales force. The second is licensed and distributed product: originator medicines sold under partnership, authorised generics manufactured locally under licence, and devices and consumer-health lines distributed for foreign principals, where Ferozsons earns manufacturing margins or distribution margins rather than owning the underlying patent. The third is its stake in BF Biosciences, whose biotech portfolio — biologics, insulin and newer diabetes therapies — addresses categories where local production can undercut imports and still earn well.
Costs follow the industry pattern, with a partnership twist. Active pharmaceutical ingredients are largely imported, so the rupee's exchange rate runs straight through the cost of sales. Skilled people are expensive and essential: regulatory specialists, biotech production staff and a nationwide field force. And the partnership model itself carries a cost — licences, technology transfer and quality systems that must satisfy not only Pakistan's regulator but also the audit standards of partners such as Gilead and Bagó. When a licensed therapy succeeds at scale, as hepatitis C treatment did, the model produces exceptional years; the same model must then find the next therapy as the epidemic it treated is, hopefully, cured into a smaller market.
A further strand deserves attention, because it explains the group's shape on the exchange. BF Biosciences is not a division but a separately listed subsidiary, with Bagó as joint-venture partner and its own expansion programme in biologics, insulin, heparins and newer diabetes therapies. That structure cuts both ways for FEROZ shareholders: the parent consolidates a fast-growing, technically distinctive business, but part of that business's value is also priced directly in BF's own counter, and part of its earnings belongs to BF's minority shareholders. Anyone valuing Ferozsons has to think of it as a sum of parts — the parent's own brands and licences, plus a stake in a listed biotech maker — rather than as a single factory with a single price list.
Institutional and public-health demand is the other strand. Hepatitis treatment in Pakistan has been driven not only by private prescriptions but by screening programmes, provincial hepatitis initiatives and hospital procurement, and a supplier embedded in that system gains volumes that ordinary brand competition does not easily dislodge. The same applies to HIV, where treatment is organised substantially through public programmes and global-health funding channels. That institutional character steadies demand, but it also ties part of the company's future to programme budgets and tender outcomes decided in ministries and donor offices — a different kind of customer risk from the retail pharmacy trade, and one more reason Ferozsons' results should be read alongside Pakistan's public-health calendar, not only its prescription market.
Strengths, risks and controversies
The strengths are reputational and structural. Ferozsons' repeated selection by Gilead — for hepatitis, for a pandemic antiviral and for HIV — is a form of third-party certification few marketing budgets could buy, and its biotech first-mover position through BF Biosciences gives it capabilities most local rivals lack. Its focus on serious, high-burden diseases aligns it with public-health programmes and institutional buyers, not only with retail prescriptions.
The risks are the mirror image. Dependence on partners means dependence on their decisions: licences can be reshaped, products superseded and global strategies changed in California or Buenos Aires without reference to Lahore. Drug-price regulation caps what can be charged for much of the portfolio while imported ingredient costs float with the dollar, squeezing margins from both sides. The hepatitis franchise faces a peculiar success risk — every patient cured shrinks the future market — and the company's growth story therefore leans on successfully repeating the trick in HIV, diabetes and biologics. None of this is hidden; it is simply the price of the partnership model, and readers should weigh it alongside gentler, more diversified peers such as Otsuka Pakistan and Hoechst Pakistan.
Exports deserve a final word in the revenue picture. Ferozsons ships its products to markets across Africa, Central Asia and the Middle East, and its partnership licences have at times carried supply rights reaching far beyond Pakistan's borders — the lenacapavir licence, for instance, covers manufacture for supply across the many low- and middle-income countries named in it. Export earnings will probably never dominate a company whose centre of gravity is the Pakistani patient, but they diversify the currency mix, keep plants utilised between domestic cycles, and test the company's quality systems against foreign regulators. In a sector where most revenue is earned in regulated rupees, even a modest hard-currency stream changes how a year feels when the exchange rate moves.
The name on the PSX
Ferozsons trades as FEROZ, a main-board pharmaceutical share with a history on the exchange stretching back, through its predecessor listings, to that claimed 1960 debut. Its register combines founding-family and sponsor holdings with institutional and public shareholders, and its listed subsidiary BF Biosciences gives investors a second, more focused way the market prices part of the same story. Ferozsons has paid cash dividends in a number of years, in the pattern typical of profitable Pakistani drugmakers, though the amount and continuity of payouts rest, as everywhere, on board decisions and cash needs in any given year.
That longevity also gives the share a particular audience. Pharmaceutical investors in Pakistan tend to sort the sector into multinational subsidiaries, large local groups and specialists; Ferozsons is the name most often filed under the third heading, and its results are consequently read against partnership news from anywhere in the world — a Gilead approval, a Bagó launch, a global-health funding round — as much as against domestic prescription data.
What kind of investor studies Ferozsons
Ferozsons suits investors who like to follow pipelines and partnerships the way others follow cement dispatches or bank deposits: the story moves when a licence is signed, a biotech line is commissioned or a global therapy is approved. It asks its followers to understand regulated pricing, licence economics and Pakistan's disease burden — and to accept that a meaningful part of the company's fate is negotiated in other companies' boardrooms. This article is educational content, not financial advice; partnership headlines are a starting point for reading the annual report, not a substitute for it.
Key takeaway: Ferozsons, public since 1960, built its name by bringing the world's hepatitis and HIV breakthroughs to Pakistan through Gilead and Bagó partnerships — a platform model whose strengths and dependencies both flow from those alliances.
